Haemonetics Corp [HAE] stock prices are up 1.86% to $68.36 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HAE shares have gain 36.69% over the last week, with a monthly amount glided 36.31%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Haemonetics Corp [NYSE: HAE] stock has seen the most recent analyst activity on August 11, 2025, when Raymond James downgraded its rating to a Outperform but kept the price target unchanged to $78 for it. Previously, Barrington Research reaffirmed its Outperform rating on August 08, 2025, and dropped its price target to $86. On August 08, 2025, downgrade downgraded it’s rating to Neutral but maintained its price target of $62 on the stock. Citigroup upgraded its rating to a Buy but stick to its price target of $90 on July 09, 2025. Robert W. Baird initiated its recommendation with a Outperform and recommended $87 as its price target on June 26, 2025. BofA Securities downgraded its rating to Underperform for this stock on February 07, 2025, and downed its price target to $68. In a note dated December 06, 2024, JP Morgan initiated an Overweight rating and provided a target price of $116 on this stock.
The stock price of Haemonetics Corp [HAE] has been fluctuating between $47.31 and $94.99 over the past year. Currently, Wall Street analysts expect the stock to reach $78 within the next 12 months. Haemonetics Corp [NYSE: HAE] shares were valued at $68.36 at the most recent close of the market. An investor can expect a potential return of 14.1% based on the average HAE price forecast.
Analyzing the HAE fundamentals
The Haemonetics Corp [NYSE:HAE] reported sales of 1.33B for trailing twelve months, representing a drop of -5.27%. Gross Profit Margin for this corporation currently stands at 0.57% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.16%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.19 and Total Capital is 0.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 66.66 points at the first support level, and at 64.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 70.72, and for the 2nd resistance point, it is at 73.07.
Ratios To Look Out For
It’s worth pointing out that Haemonetics Corp [NYSE:HAE]’s Current Ratio is 1.64. As well, the Quick Ratio is 1.03, while the Cash Ratio is 0.54. Considering the valuation of this stock, the price to sales ratio is 2.41, the price to book ratio is 3.76 and price to earnings (TTM) ratio is 19.94.
Transactions by insiders
Recent insider trading involved Llorens Josep, Former Officer, that happened on Jun 26 ’25 when 18630.0 shares were purchased. Former Officer, Strong Stewart W completed a deal on Jun 12 ’25 to buy 708.0 shares. Meanwhile, Officer Strong Stewart W bought 7705.0 shares on Jun 04 ’25.
